130.5K XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 05 Feb 2025 | 13,959 | 745,126 (3%) | 0% | 0.8 | 10,888 | Common Stock |
| Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 05 Feb 2025 | 55,260 | 689,866 (3%) | 0% | 0.8 | 43,103 | Common Stock |
| Timothy Keutzer | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 03 Feb 2025 | 24,920 | 741,439 (3%) | 0% | 0.8 | 19,438 | Common Stock |
| Timothy Keutzer | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 266,139 | 797,976 (4%) | 1% | 0 | Common Stock | |
| Timothy Keutzer | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 03 Feb 2025 | 3,974 | 794,002 (4%) | 0% | 0.8 | 3,100 | Common Stock |
| Timothy Keutzer | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 03 Feb 2025 | 27,643 | 766,359 (3%) | 0% | 0.8 | 21,562 | Common Stock |
| Sath Shukla | CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 751,407 | 1,892,216 (9%) | 3% | 0 | Common Stock | |
| Sath Shukla | CEO & President | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 03 Feb 2025 | 6,139 | 1,886,077 (9%) | 0% | 0.8 | 4,788 | Common Stock |
| Sath Shukla | CEO & President | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 03 Feb 2025 | 42,786 | 1,843,291 (9%) | 0% | 0.8 | 33,373 | Common Stock |
| Sath Shukla | CEO & President | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 03 Feb 2025 | 106,408 | 1,736,883 (9%) | 0% | 0.8 | 82,998 | Common Stock |
| Esther Rajavelu | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 100,000 | 745,409 (3%) | 0% | 0 | Common Stock | |
| Esther Rajavelu | CFO & CBO | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 03 Feb 2025 | 20,689 | 724,720 (3%) | 0% | 0.8 | 16,137 | Common Stock |
| Esther Rajavelu | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 266,139 | 645,409 (3%) | 1% | 0 | Common Stock | |
| Esther Rajavelu | CFO & CBO | Sale of securities on an exchange or to another person at price $ 1.31 per share. | 07 Nov 2024 | 23,351 | 396,515 (2%) | 0% | 1.3 | 30,590 | Common Stock |
| Esther Rajavelu | CFO & CBO | Sale of securities on an exchange or to another person at price $ 1.30 per share. | 07 Nov 2024 | 17,245 | 379,270 (1%) | 0% | 1.3 | 22,419 | Common Stock |
| Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 1.35 per share. | 27 Aug 2024 | 5,912 | 759,085 (3%) | 0% | 1.3 | 7,981 | Common Stock |
| Timothy Keutzer | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.35 per share. | 27 Aug 2024 | 2,213 | 531,837 (2%) | 0% | 1.4 | 2,988 | Common Stock |
| Sath Shukla | CEO & President | Sale of securities on an exchange or to another person at price $ 1.35 per share. | 27 Aug 2024 | 2,757 | 1,140,809 (5%) | 0% | 1.4 | 3,722 | Common Stock |
| Sath Shukla | CEO and President | Sale of securities on an exchange or to another person at price $ 1.32 per share. | 02 Aug 2024 | 14,800 | 1,161,207 (6%) | 0% | 1.3 | 19,536 | Common Stock |
| Sath Shukla | CEO and President | Sale of securities on an exchange or to another person at price $ 1.31 per share. | 02 Aug 2024 | 17,641 | 1,143,566 (5%) | 0% | 1.3 | 23,110 | Common Stock |
| Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| John C. Pottage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| Milind S. Deshpande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 71,454 (0%) | 0% | 0 | Common Stock | |
| Scott T. Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| Patrick V.J.J. Vink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| Kathleen Tregoning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| Ankit Mahadevia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 764,997 (3%) | 0% | 0 | Common Stock | |
| Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 1.37 per share. | 02 Feb 2024 | 63,795 | 744,997 (3%) | 0% | 1.4 | 87,399 | Common Stock |
| Hamed Kamal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.37 per share. | 01 Feb 2024 | 28,075 | 788,117 (4%) | 0% | 1.4 | 38,463 | Common Stock |
| Shukla Sath | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 679,501 | 1,252,001 (6%) | 3% | 0 | Common Stock | |
| Rajavelu Esther | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 119,866 | 419,866 (2%) | 0% | 0 | Common Stock | |
| Shukla Sath | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.37 per share. | 01 Feb 2024 | 30,901 | 1,221,100 (6%) | 0% | 1.4 | 42,334 | Common Stock |
| Keutzer Timothy | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 239,731 | 565,021 (2%) | 1% | 0 | Common Stock | |
| Tamara L. Joseph | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.37 per share. | 01 Feb 2024 | 30,906 | 531,615 (2%) | 0% | 1.4 | 42,341 | Common Stock |
| Keutzer Timothy | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.36 per share. | 01 Feb 2024 | 30,971 | 534,050 (2%) | 0% | 1.4 | 42,121 | Common Stock |
| Sath Shukla | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.45 per share. | 01 Feb 2024 | 45,093 | 1,176,007 (6%) | 0% | 1.5 | 65,385 | Common Stock |
| Hamed Kamal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 239,731 | 816,192 (4%) | 1% | 0 | Common Stock | |
| L. Joseph Tamara | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 239,731 | 562,521 (2%) | 1% | 0 | Common Stock | |
| Kathleen Tregoning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 35,604 | 35,604 | - | - | Stock Option (Right to Buy) | |
| Tamara L. Joseph | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 28 Aug 2023 | 1,854 | 322,790 (1%) | 0% | 1.3 | 2,336 | Common Stock |
| Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 28 Aug 2023 | 9,040 | 788,792 (4%) | 0% | 1.3 | 11,390 | Common Stock |
| Timothy Keutzer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 28 Aug 2023 | 1,854 | 325,290 (1%) | 0% | 1.3 | 2,336 | Common Stock |
| Sath Shukla | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.30 per share. | 28 Aug 2023 | 4,163 | 572,500 (2%) | 0% | 1.3 | 5,412 | Common Stock |
| Sath Shukla | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 28 Aug 2023 | 1,854 | 576,663 (2%) | 0% | 1.3 | 2,336 | Common Stock |
| Sath Shukla | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2023 | 266,000 | 578,517 (3%) | 1% | 0 | Common Stock | |
| Kamal Hamed | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 140,000 | 615,957 (3%) | 0% | 0 | Common Stock | |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.81 per share. | 03 Feb 2023 | 12,286 | 797,832 (4%) | 0% | 1.8 | 22,238 | Common Stock |
| Tamara L. Joseph | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 265,957 | 328,038 (1%) | 1% | 0 | Common Stock | |
| Tamara L. Joseph | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.86 per share. | 01 Feb 2023 | 3,394 | 324,644 (1%) | 0% | 1.9 | 6,313 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 531,914 | 810,118 (4%) | 2% | 0 | Common Stock | |
| Timothy Keutzer | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.86 per share. | 01 Feb 2023 | 3,394 | 327,144 (1%) | 0% | 1.9 | 6,313 | Common Stock |
| Timothy Keutzer | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 265,957 | 330,538 (1%) | 1% | 0 | Common Stock | |
| Sath Shukla | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.83 per share. | 01 Feb 2023 | 9,504 | 312,517 (1%) | 0% | 1.8 | 17,372 | Common Stock |
| Sath Shukla | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 265,957 | 322,021 (1%) | 1% | 0 | Common Stock | |
| Kamal Hamed | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 265,957 | 475,957 (2%) | 1% | 0 | Common Stock | |
| Patrick V.J.J. Vink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 15,471 | 15,471 | - | - | Stock Option (Right to Buy) | |
| Kathleen Tregoning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 30,943 | 30,943 | - | - | Stock Option (Right to Buy) | |
| Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| John C. Pottage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Milind S. Deshpande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 31,454 (0%) | 0% | 0 | Common Stock | |
| Scott T. Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Patrick V.J.J. Vink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Kathleen Tregoning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Kamal Hamed | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2022 | 210,000 | 210,000 (1%) | 1% | 0 | Common Stock | |
| Tamara L. Joseph | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 38,014 | 62,081 (0%) | 0% | 0 | Common Stock | |
| Tamara L. Joseph | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 53,190 | 53,190 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 187,730 | 187,730 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 134,168 | 278,204 (1%) | 0% | 0 | Common Stock | |
| Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 38,014 | 63,581 (0%) | 0% | 0 | Common Stock | |
| Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 53,190 | 53,190 | - | - | Stock Option (Right to Buy) | |
| Timothy Keutzer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 38,014 | 64,581 (0%) | 0% | 0 | Common Stock | |
| Timothy Keutzer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 53,190 | 53,190 | - | - | Stock Option (Right to Buy) | |
| David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 53,190 | 53,190 | - | - | Stock Option (Right to Buy) | |
| David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 38,014 | 62,081 (0%) | 0% | 0 | Common Stock | |
| Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 2,214 | 2,214 | - | - | Stock Option (Right to Buy) | |
| Patrick V.J.J. Vink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 2,214 | 2,214 | - | - | Stock Option (Right to Buy) | |
| Kathleen Tregoning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 4,428 | 4,428 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2021 | 8,000 | 486,809 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.58 per share. | 27 Dec 2021 | 8,000 | 144,036 (0%) | 0% | 14.6 | 116,666 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 27 Dec 2021 | 8,000 | 152,036 (0%) | 0% | 5.9 | 47,200 | Common Stock |
| Kathleen Tregoning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Tamara L. Joseph | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2021 | 24,067 | 24,067 (0%) | 0% | 0 | Common Stock | |
| Ankit Mahadevia | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2021 | 78,219 | 144,036 (0%) | 0% | 0 | Common Stock | |
| Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2021 | 24,067 | 25,567 (0%) | 0% | 0 | Common Stock | |
| Timothy Keutzer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2021 | 24,067 | 26,567 (0%) | 0% | 0 | Common Stock | |
| David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2021 | 24,067 | 24,067 (0%) | 0% | 0 | Common Stock | |
| Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| John C. Pottage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Milind S. Deshpande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Scott T. Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Patrick Vink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Ankit Mahadevia | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 179,319 | 179,319 | - | - | Stock Option (Right to Buy) | |
| Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 57,432 | 57,432 | - | - | Stock Option (Right to Buy) | |
| Timothy Keutzer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 57,432 | 57,432 | - | - | Stock Option (Right to Buy) | |
| David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 57,432 | 57,432 | - | - | Stock Option (Right to Buy) | |
| Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 1,314 | 1,314 | - | - | Stock Option (right to buy) | |
| Milind S. Deshpande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 2,629 | 2,629 | - | - | Stock Option (right to buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 2,629 | 2,629 | - | - | Stock Option (right to buy) | |
| Patrick Vink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 1,314 | 1,314 | - | - | Stock Option (right to buy) | |
| Cristina Larkin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 12,000 | 8,434 | - | - | Stock Option (Right to Buy) | |
| Cristina Larkin | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 16 Dec 2020 | 12,000 | 1,500 (0%) | 0% | 19 | 228,000 | Common Stock |
| Cristina Larkin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 16 Dec 2020 | 12,000 | 13,500 (0%) | 0% | 5.9 | 70,800 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2020 | 2,137 | 502,179 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2020 | 7,370 | 494,809 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.27 per share. | 03 Nov 2020 | 2,137 | 65,817 (0%) | 0% | 14.3 | 30,490 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 03 Nov 2020 | 2,137 | 67,954 (0%) | 0% | 5.9 | 12,608 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.43 per share. | 03 Nov 2020 | 7,370 | 65,817 (0%) | 0% | 14.4 | 106,335 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 03 Nov 2020 | 7,370 | 73,187 (0%) | 0% | 5.9 | 43,483 | Common Stock |
| Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| John C. Pottage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Milind S. Deshpande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Scott T. Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Patrick Vink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Oct 2020 | 20 | 504,316 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 23 Oct 2020 | 20 | 65,817 (0%) | 0% | 14.3 | 285 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 23 Oct 2020 | 20 | 65,837 (0%) | 0% | 5.9 | 118 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2020 | 105 | 504,336 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 13 Oct 2020 | 105 | 65,922 (0%) | 0% | 5.9 | 620 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.28 per share. | 13 Oct 2020 | 14,367 | 65,817 (0%) | 0% | 14.3 | 205,212 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 13 Oct 2020 | 14,367 | 80,184 (0%) | 0% | 5.9 | 84,765 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2020 | 14,367 | 504,441 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 13 Oct 2020 | 105 | 65,817 (0%) | 0% | 14.2 | 1,496 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 08 Sep 2020 | 774 | 66,591 (0%) | 0% | 5.9 | 4,567 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 08 Sep 2020 | 774 | 65,817 (0%) | 0% | 14.3 | 11,030 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2020 | 774 | 518,808 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.31 per share. | 07 Jul 2020 | 2,293 | 65,817 (0%) | 0% | 14.3 | 32,807 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 07 Jul 2020 | 754 | 66,571 (0%) | 0% | 5.9 | 4,449 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 07 Jul 2020 | 754 | 65,817 (0%) | 0% | 14.3 | 10,745 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 07 Jul 2020 | 2,293 | 68,110 (0%) | 0% | 5.9 | 13,529 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2020 | 754 | 521,875 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2020 | 2,293 | 519,582 | - | - | Stock Option (Right to Buy) | |
| Scott T. Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 2,642 | 522,629 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 3,880 | 525,271 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 8,045 | 529,151 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 2,613 | 537,196 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 22 Jun 2020 | 2,642 | 65,817 (0%) | 0% | 14.3 | 37,650 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 22 Jun 2020 | 2,642 | 68,459 (0%) | 0% | 5.9 | 15,588 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.28 per share. | 22 Jun 2020 | 3,880 | 65,817 (0%) | 0% | 14.3 | 55,420 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 22 Jun 2020 | 3,880 | 69,697 (0%) | 0% | 5.9 | 22,892 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.33 per share. | 22 Jun 2020 | 8,045 | 65,817 (0%) | 0% | 14.3 | 115,264 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 22 Jun 2020 | 8,045 | 73,862 (0%) | 0% | 5.9 | 47,466 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.30 per share. | 22 Jun 2020 | 2,613 | 65,817 (0%) | 0% | 14.3 | 37,365 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 22 Jun 2020 | 2,613 | 68,430 (0%) | 0% | 5.9 | 15,417 | Common Stock |
| Ankit Mahadevia | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Timothy Keutzer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 2,704 | 2,704 | - | - | Stock Option (right to buy) | |
| Milind S. Deshpande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 5,408 | 5,408 | - | - | Stock Option (right to buy) | |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 5,408 | 5,408 | - | - | Stock Option (right to buy) | |
| Patrick Vink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 5,408 | 5,408 | - | - | Stock Option (right to buy) | |
| Frank E. Thomas | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| John C. Pottage | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| Milind S. Deshpande | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| Jean-Francois Formela | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| Cynthia Smith | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| Patrick Volkert Jozef Joihannes Vink | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| Cynthia Smith | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 12,146 | 12,146 | - | - | Stock Option (right to buy) | |
| Joel Sendek | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy | |
| Thomas R. Parr | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| John C. Pottage | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2018 | 12,146 | 12,146 | - | - | Stock Option (right to buy) | |
| Joel Sendek | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jul 2018 | 2,000 | 165,833 | - | - | Stock Option (Right to Buy) | |
| Joel Sendek | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.50 per share. | 05 Jul 2018 | 2,000 | 15,181 (0%) | 0% | 17.5 | 35,000 | Common Stock |
| Joel Sendek | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 05 Jul 2018 | 2,000 | 17,181 (0%) | 0% | 5.9 | 11,800 | Common Stock |
| Ankit Mahadevia | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 05 Jul 2018 | 3,076 | 68,893 (0%) | 0% | 5.9 | 18,148 | Common Stock |
| Ankit Mahadevia | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jul 2018 | 3,076 | 120,488 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jul 2018 | 1,600 | 118,888 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.62 per share. | 05 Jul 2018 | 3,076 | 65,817 (0%) | 0% | 17.6 | 54,204 | Common Stock |
| Ankit Mahadevia | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 05 Jul 2018 | 1,600 | 67,417 (0%) | 0% | 5.9 | 9,440 | Common Stock |
| Ankit Mahadevia | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.50 per share. | 05 Jul 2018 | 500 | 66,917 (0%) | 0% | 17.5 | 8,750 | Common Stock |
| Ankit Mahadevia | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.55 per share. | 05 Jul 2018 | 100 | 66,817 (0%) | 0% | 17.6 | 1,755 | Common Stock |
| Ankit Mahadevia | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.58 per share. | 05 Jul 2018 | 400 | 66,417 (0%) | 0% | 17.6 | 7,032 | Common Stock |
| Ankit Mahadevia | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.62 per share. | 05 Jul 2018 | 100 | 66,317 (0%) | 0% | 17.6 | 1,762 | Common Stock |
| Ankit Mahadevia | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.71 per share. | 05 Jul 2018 | 100 | 66,217 (0%) | 0% | 17.7 | 1,771 | Common Stock |
| Ankit Mahadevia | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.90 per share. | 05 Jul 2018 | 200 | 66,017 (0%) | 0% | 17.9 | 3,580 | Common Stock |
| Ankit Mahadevia | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.92 per share. | 05 Jul 2018 | 200 | 65,817 (0%) | 0% | 17.9 | 3,584 | Common Stock |
| Cristina Larkin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 05 Jul 2018 | 4,000 | 5,500 (0%) | 0% | 5.9 | 23,600 | Common Stock |
| Cristina Larkin | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 17.50 per share. | 05 Jul 2018 | 4,000 | 1,500 (0%) | 0% | 17.5 | 70,000 | Common Stock |
| Cristina Larkin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jul 2018 | 4,000 | 20,434 | - | - | Stock Option (Right to Buy) | |
| Frank E. Thomas | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| Milind S. Deshpande | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| David P. Southwell | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| Jean-Francois Formela | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| Patrick Volkert Jozef Joihannes Vink | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| Casper Breum | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 6,073 | 6,073 | - | - | Stock Option (right to buy) | |
| David P. Southwell | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2018 | 12,146 | 12,146 | - | - | Stock Option (right to buy) | |
| David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2018 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Joel Sendek | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2017 | 27,795 | 27,795 | - | - | Stock Option (Right to Buy) | |
| Thomas R. Parr | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2017 | 36,134 | 36,134 | - | - | Stock Option (Right to Buy) | |
| Ankit Mahadevia | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2017 | 125,079 | 125,079 | - | - | Stock Option (Right to Buy) | |
| Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2017 | 62,540 | 62,540 | - | - | Stock Option (Right to Buy) | |
| Jean-Francois Formela | None | 06 Nov 2017 | 1,492,645 | 0 | - | - | Junior Preferred Stock | ||
| Jean-Francois Formela | None | 06 Nov 2017 | 1,250,000 | 0 | - | - | Series B Preferred Stock | ||
| Jean-Francois Formela | None | 06 Nov 2017 | 3,119,633 | 0 | - | - | Series C Preferred Stock | ||
| Jean-Francois Formela | None | Purchase of securities on an exchange or from another person at price $ 14.00 per share. | 06 Nov 2017 | 428,571 | 2,408,128 (17%) | 3% | 14 | 5,999,994 | Common Stock |
| Jean-Francois Formela | None | 06 Nov 2017 | 602,589 | 1,979,557 (14%) | 4% | 0 | Common Stock | ||
| Jean-Francois Formela | None | 06 Nov 2017 | 513,318 | 1,376,968 (9%) | 3% | 0 | Common Stock | ||
| Jean-Francois Formela | None | 06 Nov 2017 | 328,992 | 863,650 (6%) | 2% | 0 | Common Stock | ||
| Jean-Francois Formela | None | 06 Nov 2017 | 246,272 | 534,658 (3%) | 1% | 0 | Common Stock | ||
| Jean-Francois Formela | None | 06 Nov 2017 | 245,605 | 288,386 (2%) | 1% | 0 | Common Stock | ||
| Jean-Francois Formela | None | 06 Nov 2017 | 3,662,178 | 0 | - | - | Series C Preferred Stock | ||
| Jean-Francois Formela | None | 06 Nov 2017 | 982,906 | 0 | - | - | Series A Preferred Stock | ||
| Joel Sendek | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 14.00 per share. | 06 Nov 2017 | 5,000 | 15,181 (0%) | 0% | 14 | 70,000 | Common Stock |
| Joel Sendek | Chief Financial Officer | 06 Nov 2017 | 61,880 | 0 | - | - | Series C Preferred Stock | ||
| Joel Sendek | Chief Financial Officer | 06 Nov 2017 | 10,181 | 10,181 (0%) | 0% | 0 | Common Stock | ||
| Casper Breum | None | 06 Nov 2017 | 408,937 | 877,489 (6%) | 2% | 0 | Common Stock | ||
| Casper Breum | None | 06 Nov 2017 | 2,485,272 | 0 | - | - | Series C Preferred Stock | ||
| Casper Breum | None | 06 Nov 2017 | 681,818 | 0 | - | - | Series B Preferred Stock | ||
| Casper Breum | None | Purchase of securities on an exchange or from another person at price $ 14.00 per share. | 06 Nov 2017 | 214,285 | 1,091,774 (7%) | 1% | 14 | 2,999,990 | Common Stock |
| Casper Breum | None | 06 Nov 2017 | 179,450 | 468,552 (3%) | 1% | 0 | Common Stock | ||
| Casper Breum | None | 06 Nov 2017 | 1,153,846 | 0 | - | - | Series A Preferred Stock | ||
| Casper Breum | None | 06 Nov 2017 | 289,102 | 289,102 (2%) | 2% | 0 | Common Stock | ||
| Cristina Larkin | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 14.00 per share. | 06 Nov 2017 | 1,500 | 1,500 (0%) | 0% | 14 | 21,000 | Common Stock |
| Vikas Goyal | None | 06 Nov 2017 | 982,906 | 0 | - | - | Series A preferred stock | ||
| Vikas Goyal | None | 06 Nov 2017 | 328,992 | 819,411 (5%) | 2% | 0 | Common Stock | ||
| Vikas Goyal | None | 06 Nov 2017 | 606,024 | 1,425,435 (10%) | 4% | 0 | Common Stock | ||
| Vikas Goyal | None | Purchase of securities on an exchange or from another person at price $ 14.00 per share. | 06 Nov 2017 | 428,571 | 1,854,006 (13%) | 3% | 14 | 5,999,994 | Common Stock |
| Vikas Goyal | None | 06 Nov 2017 | 3,683,045 | 0 | - | - | Series C preferred stock | ||
| Vikas Goyal | None | 06 Nov 2017 | 246,272 | 490,419 (3%) | 1% | 0 | Common Stock | ||
| Vikas Goyal | None | 06 Nov 2017 | 244,147 | 244,147 (1%) | 1% | 0 | Common Stock | ||
| Vikas Goyal | None | 06 Nov 2017 | 1,250,000 | 0 | - | - | Series B preferred stock | ||
| Vikas Goyal | None | 06 Nov 2017 | 1,483,784 | 0 | - | - | Junior preferred stock |